12/4
11:50 pm
tara
Protara Announces Pricing of $75 Million Public Offering [Yahoo! Finance]
Medium
Report
Protara Announces Pricing of $75 Million Public Offering [Yahoo! Finance]
12/4
10:03 pm
tara
Protara Announces Pricing of $75 Million Public Offering
Medium
Report
Protara Announces Pricing of $75 Million Public Offering
12/4
04:57 pm
tara
Protara Announces Proposed Public Offering [Yahoo! Finance]
Medium
Report
Protara Announces Proposed Public Offering [Yahoo! Finance]
12/4
04:15 pm
tara
Protara Announces Proposed Public Offering
High
Report
Protara Announces Proposed Public Offering
12/4
07:33 am
tara
Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]
Medium
Report
Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]
12/3
02:19 pm
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
12/3
08:00 am
tara
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Medium
Report
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
12/1
05:32 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 [Yahoo! Finance]
High
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 [Yahoo! Finance]
12/1
04:15 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
High
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
11/19
12:08 pm
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Medium
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
11/19
08:00 am
tara
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Low
Report
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
11/18
04:57 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 [Yahoo! Finance]
Low
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 [Yahoo! Finance]
11/18
04:30 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
Low
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
11/17
08:00 am
tara
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
Low
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
11/10
08:00 am
tara
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
High
Report
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
11/4
04:05 pm
tara
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
Low
Report
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
10/1
04:03 pm
tara
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/24
07:55 am
tara
A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index [Yahoo! Finance]
High
Report
A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index [Yahoo! Finance]
9/22
07:03 am
tara
What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders [Yahoo! Finance]
Low
Report
What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders [Yahoo! Finance]
9/21
06:44 am
tara
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy' Penny Stocks [Yahoo! Finance]
High
Report
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy' Penny Stocks [Yahoo! Finance]